I would have remembered if there was any RWE other than a few anecdotes.
Nice and encouraging as those anecdotes are there isn’t enough RWE for approval at this point.
The most recent scientific and peer reviewed data showed 2 AD patients achieving improvement and stabilisation over 148 weeks while the rest declined and some faster than SOC historical comparison.
Fortunately though we will soon have readout from the first ever Anavex controlled P2 trial, which is awaited with anticipation and hope.
Market Data 
Markets 
AI
